JPWO2022246183A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022246183A5 JPWO2022246183A5 JP2023572230A JP2023572230A JPWO2022246183A5 JP WO2022246183 A5 JPWO2022246183 A5 JP WO2022246183A5 JP 2023572230 A JP2023572230 A JP 2023572230A JP 2023572230 A JP2023572230 A JP 2023572230A JP WO2022246183 A5 JPWO2022246183 A5 JP WO2022246183A5
- Authority
- JP
- Japan
- Prior art keywords
- thiourea
- antibody
- targeted radiopharmaceutical
- radiopharmaceutical
- targeted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191499P | 2021-05-21 | 2021-05-21 | |
| US202163191506P | 2021-05-21 | 2021-05-21 | |
| US63/191,499 | 2021-05-21 | ||
| US63/191,506 | 2021-05-21 | ||
| PCT/US2022/030234 WO2022246183A1 (en) | 2021-05-21 | 2022-05-20 | Trivalent radioisotope bio-targeted radiopharmaceutical, methods of preparation and use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024519970A JP2024519970A (ja) | 2024-05-21 |
| JP2024519970A5 JP2024519970A5 (https=) | 2025-06-13 |
| JPWO2022246183A5 true JPWO2022246183A5 (https=) | 2025-06-13 |
Family
ID=84140859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516731A Pending JP2024520180A (ja) | 2021-05-21 | 2022-05-20 | ウロキナーゼプラスミノーゲンアクチベーター受容体標的放射性医薬品 |
| JP2023572230A Pending JP2024519970A (ja) | 2021-05-21 | 2022-05-20 | 三価放射性同位体生物標的放射性医薬品、調製方法及び使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516731A Pending JP2024520180A (ja) | 2021-05-21 | 2022-05-20 | ウロキナーゼプラスミノーゲンアクチベーター受容体標的放射性医薬品 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220378956A1 (https=) |
| EP (2) | EP4341296A4 (https=) |
| JP (2) | JP2024520180A (https=) |
| KR (1) | KR20240035757A (https=) |
| AU (2) | AU2022276444A1 (https=) |
| CA (1) | CA3223227A1 (https=) |
| IL (1) | IL308731A (https=) |
| MX (1) | MX2023013836A (https=) |
| WO (2) | WO2022246183A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024147853A1 (en) * | 2023-01-05 | 2024-07-11 | NorthStar Medical Technologies, LLC | Method for stacked elution of mother-daughter radionuclides |
| CN120712109A (zh) * | 2023-01-18 | 2025-09-26 | 库拉赛特股份公司 | 用于位点特异性uPAR靶向的放射性核素标记肽缀合物 |
| US20240412886A1 (en) * | 2023-06-07 | 2024-12-12 | NorthStar Medical Technologies, LLC | Liquid Deposition of Salts for Bombardment Target Preparation |
| WO2025207781A1 (en) * | 2024-03-26 | 2025-10-02 | Monopar Therapeutics Inc. | Antibody radioisotope constructs |
| WO2026019458A1 (en) * | 2024-07-19 | 2026-01-22 | Monopar Therpeutics, Inc | Squaramide bi-functional chelators and associated radiopharmaceuticals and methods of use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334371A (en) * | 1988-07-20 | 1994-08-02 | Schering Aktiengesellschaft | Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI |
| RU2182022C1 (ru) * | 2001-05-24 | 2002-05-10 | Российская медицинская академия последипломного образования МЗ РФ | Способ лечения онкологических заболеваний щитовидной железы |
| CN101022830A (zh) * | 2004-05-25 | 2007-08-22 | 阿特努奥恩公司 | 抑制下游 u P A R相互作用并结合了尿激酶类纤溶酶原激发剂（ u P A）与其受体（ u P A R）的复合物的配位体：在诊断或治疗中的识别和用途 |
| KR20120064120A (ko) * | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| FR2883562B1 (fr) * | 2005-03-24 | 2009-02-27 | Guerbet Sa | Chelates lipophiles et leur utilisation en imagerie |
| DK2117571T3 (en) * | 2006-12-08 | 2017-05-08 | Monopar Therapeutics Inc | Urokinase-type plasminogen activator receptor epitope |
| LT4095130T (lt) * | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| ES2784684T3 (es) * | 2015-02-26 | 2020-09-29 | Sciencons AS | Soluciones de radiofármacos con propiedades ventajosas |
| WO2016191186A1 (en) * | 2015-05-22 | 2016-12-01 | Memorial Sloan Kettering Cancer Center | Systems and methods for determining optimum patient-specific antibody dose for tumor targeting |
| AU2017281940C1 (en) * | 2016-06-24 | 2024-11-07 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| US11629201B2 (en) * | 2017-05-24 | 2023-04-18 | ITM Isotope Technologies Munich SE | PSMA-binding agents and uses thereof |
| IL293375A (en) * | 2019-12-03 | 2022-07-01 | Debiopharm Res & Manufacturing S A | reactive couplings |
| CA3182769A1 (en) * | 2020-06-15 | 2021-12-23 | Andrew P. Mazar | Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease |
| WO2022123462A1 (en) * | 2020-12-09 | 2022-06-16 | 3B Pharmaceuticals Gmbh | Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof |
-
2022
- 2022-05-20 JP JP2024516731A patent/JP2024520180A/ja active Pending
- 2022-05-20 EP EP22805584.4A patent/EP4341296A4/en active Pending
- 2022-05-20 MX MX2023013836A patent/MX2023013836A/es unknown
- 2022-05-20 IL IL308731A patent/IL308731A/en unknown
- 2022-05-20 EP EP22805562.0A patent/EP4341265A4/en active Pending
- 2022-05-20 US US17/749,574 patent/US20220378956A1/en active Pending
- 2022-05-20 JP JP2023572230A patent/JP2024519970A/ja active Pending
- 2022-05-20 US US17/749,763 patent/US20220409751A1/en active Pending
- 2022-05-20 AU AU2022276444A patent/AU2022276444A1/en active Pending
- 2022-05-20 KR KR1020237044222A patent/KR20240035757A/ko active Pending
- 2022-05-20 CA CA3223227A patent/CA3223227A1/en active Pending
- 2022-05-20 AU AU2022276433A patent/AU2022276433A1/en active Pending
- 2022-05-20 WO PCT/US2022/030234 patent/WO2022246183A1/en not_active Ceased
- 2022-05-20 WO PCT/US2022/030272 patent/WO2022246210A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7650938B2 (ja) | 鉛またはトリウム放射性核種に連結されたｐｓｍａ標的化化合物を含む錯体 | |
| Davis et al. | Comparison of 225actinium chelates: tissue distribution and radiotoxicity | |
| Miederer et al. | Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications | |
| US4454106A (en) | Use of metal chelate conjugated monoclonal antibodies | |
| US9433690B1 (en) | Radiopharmaceutical solutions with advantageous properties | |
| JP6734350B2 (ja) | 有利な特性を有する放射性医薬溶液 | |
| JPH0582368B2 (https=) | ||
| JP2007297404A (ja) | 腫瘍造影剤としてのヌクレオチドポリリン酸に結合された放射性核種 | |
| CN117836011A (zh) | 将生物制剂与多种螯合剂组合的方法和材料 | |
| US20060228297A1 (en) | Thorium-227 for use in radiotherapy of soft tissue disease | |
| Park et al. | Recent advances in radiopharmaceutical application of matched-pair radiometals | |
| JPWO2022246183A5 (https=) | ||
| EP1617876B1 (en) | Thorium-227 for use in radiotherapy of soft tissue disease | |
| EP3061464B1 (en) | Radiopharmaceutical solutions with advantageous properties | |
| JP2025503096A (ja) | がんの処置および撮像のための複合体 | |
| US20070009436A1 (en) | Radionuclide nanoparticles encased by inorganic shell having vector biomolecules attached thereto | |
| JPH0582370B2 (https=) | ||
| Vallabhajosula | Metal Radionuclides for Molecular Imaging | |
| Sowa Dumond et al. | Concepts and issues for therapeutic radiopharmaceuticals | |
| JPH10307138A (ja) | 腫瘍診断剤および治療剤 | |
| RU2795398C2 (ru) | Комплекс, содержащий нацеливающееся на psma соединение, связанное с радионуклидом свинца или тория | |
| Varvarigou et al. | Development of radioactively labelled cancer seeking biomolecules for targeted radiotherapy | |
| HK1228276B (en) | Radiopharmaceutical solutions with advantageous properties | |
| HK1228276A1 (en) | Radiopharmaceutical solutions with advantageous properties | |
| Macklis et al. | Metallothionein bioconjugates as delivery vehicles for bismuth-212 alpha particle therapy |